Bortezomib is a proteasome inhibitor is FDA approved for treatment of Multiple myeloma. Paclitaxel, a mitotic inhibitor drug FDA approved for treating lung, ovarian, breast, head and neck cancers and advanced Kaposi’s sarcoma. Both are in clinical trial for bcr/abl positive Leukaemias. The authors of this abstract have found that a combination of Bortezomib and Paclitaxel in mouse studies have shown a synergistic action against Baf3 Bcr-Abl T315I cell lines and believe this combination would be a promising strategy for imatinib resistant CML showing the T315i mutation in particular.
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=c54ee160-e481...